Eterna Therapeutics Inc. (ERNA)

NASDAQ: ERNA · IEX Real-Time Price · USD
2.240
-0.030 (-1.32%)
At close: Mar 27, 2024, 4:00 PM
2.460
+0.220 (9.82%)
After-hours: Mar 27, 2024, 6:53 PM EDT

Company Description

Eterna Therapeutics Inc. operates as a preclinical-stage, biopharmaceutical company.

The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming.

It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022.

Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

Eterna Therapeutics Inc.
Eterna Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Sanjeev Luther

Contact Details

Address:
1035 Cambridge Street, Suite 18a
Cambridge, Massachusetts 02141
United States
Phone (212) 582-1199
Website brooklynitx.com

Stock Details

Ticker Symbol ERNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000748592
ISIN Number US1140822099
Employer ID 31-1103425
SIC Code 2834

Key Executives

Name Position
Sandra M. Gurrola Principal Financial and Accounting Officer and Senior Vice President of Finance
Sanjeev Luther Chief Executive Officer, President and Director
Dorothy J. Clarke General Counsel and Director
Megan Yung Chief Strategy Officer

Latest SEC Filings

Date Type Title
Mar 22, 2024 8-K Current Report
Mar 18, 2024 10-K/A [Amend] Annual report
Mar 14, 2024 10-K Annual Report
Feb 16, 2024 8-K Current Report
Jan 31, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 424B3 Prospectus
Jan 22, 2024 EFFECT Notice of Effectiveness
Jan 19, 2024 8-K Current Report
Jan 19, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 17, 2024 UPLOAD Filing